RESEARCH TRIANGLE PARK, NC--(Marketwire - July 8, 2008) - New research released last week by
pharmaceutical business intelligence firm Cutting Edge Information finds that
the oncology market is currently dominated by three companies -- Roche, Amgen
and Novartis.
This new report, "Oncology Market Forecast to 2013," examines the oncology
portfolios and pipelines at the top fourteen companies in oncology. It analyzes
the current market value of each company's oncology products, as well as the
company's forecasted positioning in 2013. To view a brochure, please visit
http://www.cuttingedgeinfo.com/oncology.
CEI analysts forecast that the oncology market will grow from $57 billion in
2007 to more than $90 billion in 2013. To combat the nightmare of patent
expirations on their top-selling drugs, large pharma companies are investing in
oncology development. While Roche will continue to hold around 28% of the
oncology market, other top companies will slowly reap the rewards of current
development. By 2013, nine drug companies are expected to hit sales of more
than $4 billion from their oncology portfolios.
According to Eric Bolesh, research team leader at Cutting Edge Information,
"Companies across the industry are investing hundreds of millions of dollars in
oncology R&D and licensing. This area will be increasingly dominant in the next
five to ten years."
The 420+ page report examines more than 130 drugs and provides market analysis
on multiple levels, including:
Individual Drug Profiles -- Drug profiles include information about drugs'
competitive, strategic and market growth positions based on the following
information:
-- Past financial performance and future prospects
-- Patent/litigation information
-- Development progress across all indications
-- Market-changing events, including competitor patent expirations and trial
results
Oncology Indication Market Outlook -- Detailed outlooks for the breast,
colorectal, lung, prostate cancer and leukemia markets. These outlooks are
based on the following included information:
-- Epidemiology
-- Drug sales & forecasts
-- Pipeline summaries
-- Market events
-- Marketed products
Company Profiles -- Oncology breakdowns for 14 pharmaceutical and biotechnology
companies. These firms have established oncology franchises or exciting
development pipelines for new cancer compounds. Research includes:
-- Market share and oncology revenue
-- Competitive and strategic positioning in the oncology market
-- Company performance -- strengths, weaknesses and competitive threats
-- Drug-by-drug examination of company's oncology pipeline
Contact Information: Contact Information:
Eric Bolesh
919-433-0209